Kailera Therapeutics Registration Statement Effectiveness

Ticker: KLRA · Form: EFFECT · Filed: Apr 17, 2026

Sentiment: neutral

Topics: registration-statement, effectiveness, sec-filing

TL;DR

Kailera Therapeutics' registration statement is now effective with the SEC as of 4/17/2026.

AI Summary

Kailera Therapeutics, Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 17, 2026. The filing, with SEC Accession No. 9999999995-26-001217, relates to Act 33 and File No. 333-294690. The company's mailing and business address is 180 Third Avenue, 4th Floor, Waltham, MA 02451.

Why It Matters

This filing signifies that Kailera Therapeutics has met the SEC's requirements for its registration statement, potentially paving the way for a public offering or other securities transactions.

Risk Assessment

Risk Level: low — This is a routine administrative filing confirming the effectiveness of a registration statement, not a filing detailing significant financial events or changes.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of an EFFECT filing?

An EFFECT filing signifies that a registration statement filed with the SEC has become effective, meaning the securities can now be offered to the public.

When did Kailera Therapeutics' registration statement become effective?

The registration statement for Kailera Therapeutics, Inc. became effective on April 16, 2026.

What is the SEC Accession Number for this filing?

The SEC Accession Number for this filing is 9999999995-26-001217.

What is Kailera Therapeutics' business address?

Kailera Therapeutics, Inc.'s business address is 180 Third Avenue, 4th Floor, Waltham, MA 02451.

What industry is Kailera Therapeutics in?

Kailera Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).

Filing Details

This Form EFFECT (Form EFFECT) was filed with the SEC on April 17, 2026 regarding Kailera Therapeutics, Inc. (KLRA).

View full filing on EDGAR

View on Read The Filing